A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
P. Moreau
No relevant relationships to disclose
A. P. Palumbo
Consultant or Advisory Role - Celgene; Janssen-Cilag
Honoraria - Amgen; Celgene; Janssen-Cilag; Merck
A. K. Stewart
No relevant relationships to disclose
V. Rajkumar
No relevant relationships to disclose
A. J. Jakubowiak
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Centocor Ortho Biotech; Exelixis; Millennium
Honoraria - Bristol-Myers Squibb; Celgene; Centocor Ortho Biotech; Exelixis; Millennium
K. Halka
No relevant relationships to disclose
S. Goranov
No relevant relationships to disclose
H. Bumbea
No relevant relationships to disclose
K. B. Pendergrass
No relevant relationships to disclose
A. Lupu
No relevant relationships to disclose
A. Dimopoulos
No relevant relationships to disclose
A. O. Rocafiguera
No relevant relationships to disclose
J. G. Gandhi
No relevant relationships to disclose
G. Mihaylov
No relevant relationships to disclose
T. Masszi
No relevant relationships to disclose
J. Matous
No relevant relationships to disclose
G. Fonseca
No relevant relationships to disclose
R. Bryce
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
D. S. D. Siegel
Consultant or Advisory Role - Celgene; Millennium
Honoraria - Celgene; Millennium